Discovery of novel cMET-targeting antibody Fab drug conjugates as potential treatment for solid tumors with highly expressed cMET

References

• Birchmeier C, Birchmeier W, Gherardi E, et al. Met, Metastasis, Motility and More. Nat Rev Mol Cell Biol. 2003 Dec 1;4(12):915–925. doi: 10.1038/nrm1261
   PubMed Web of Science ®Google Scholar
• Organ S, Tsao M-S. An overview of the c-MET signaling pathway. Ther Adv Med Oncol. 2011;3(1 Suppl):S7–S19. doi: 10.1177/1758834011422556
   PubMedGoogle Scholar
• Tsarfaty I, Rong S, Resau JH, et al. The Met proto-oncogene mesenchymal to epithelial cell conversion. Science. 1994;263(5143):98–101. doi: 10.1126/science.7505952
   PubMed Web of Science ®Google Scholar
• Schmidt C, Bladt F, Goedecke S, et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature. 1995;373(6516):699–702. doi: 10.1038/373699a0
   PubMed Web of Science ®Google Scholar
• Uehara Y, Minowa O, Mori C, et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature. 1995;373(6516):702–705. doi: 10.1038/373702a0
   PubMed Web of Science ®Google Scholar
• Gherardi E, Birchmeier W, Birchmeier C, et al. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012 Jan 24;12(2):89–103. doi: 10.1038/nrc3205
   PubMed Web of Science ®Google Scholar
• Faiella A, Riccardi F, Carteni G, et al. The emerging role of c-Met in carcinogenesis and clinical implications as a possible therapeutic target. J Oncol. 2022 Jan 13;2022:1–12. doi: 10.1155/2022/5179182
   Web of Science ®Google Scholar
• Zhang Y, Xia M, Jin K, et al. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer. 2018 Feb 19;17(1). doi: 10.1186/s12943-018-0796-y
   Google Scholar
• Parikh R, Wang P, Beumer J, et al. The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment. Onco Targets Ther. 2014 Jun 11;7:969–983. doi: 10.2147/OTT.S40241
   PubMed Web of Science ®Google Scholar
• Ma P, Tretiakova M, MacKinnon A, et al. Expression and mutational analysis of MET in human solid Cancers. Genes Chromosomes Cancer. 2008 Dec;47(12):1025–1037. doi: 10.1002/gcc.20604
   PubMed Web of Science ®Google Scholar
• Di Renzo M, Narsimhan R, Olivero M, et al. Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene. 1991 Nov;6(11):1997–2203. PMID: 1719465
   PubMed Web of Science ®Google Scholar
• Chiriaco C, Donini C, Cortese M, et al. Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy. J Exp Clin Cancer Res. 2022 Oct 21;41(1):309. doi: 10.1186/s13046-022-02479-y
   PubMed Web of Science ®Google Scholar
• Dong Y, Xu J, Sun B, et al. MET-Targeted therapies and clinical outcomes: a systematic literature review. Mol Diagn Ther. 2022 Mar 10;26(2):203–227. doi: 10.1007/s40291-021-00568-w
   PubMed Web of Science ®Google Scholar
• Santarpia M, Massafra M, Gebbia V, et al. A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations. Transl Lung Cancer Res. 2021;10(3):1536–1556. doi: 10.21037/tlcr-20-1113
   PubMed Web of Science ®Google Scholar
• Prat M, Crepaldi T, Pennacchietti S, et al. Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci. [1997 Dec 23];111(2):237–247. doi: 10.1242/jcs.111.2.237
   PubMedGoogle Scholar
• Pietronave S, Forte G, Locamo D, et al. Agonist monoclonal antibodies against HGF receptor protect cardiac muscle cells from apoptosis. Am J Physiol Heart Circ Physiol. [2010 Jan 8];298(4):H1155–H1165. doi: 10.1152/ajpheart.01323.2008
   PubMed Web of Science ®Google Scholar
• Merchant M, Ma X, Maun H, et al. Monovalent antibody design and mechanism of action of Onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Nat Acad Sci. [2013 Jul 2];110(32):E2987–E2996. doi: 10.1073/pnas.1302725110
   PubMed Web of Science ®Google Scholar
• Liu L, Zeng W, Wortinger M, et al. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-Dependent and HGF-Independent MET activation and tumor growth. Clin Cancer Res. 2014 Sep 17;20(23):6059–6070. doi: 10.1158/1078-0432.CCR-14-0543
   PubMed Web of Science ®Google Scholar
• Wang J, Goetsch L, Tucker L, et al. Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification. BMC Cancer. 2016 Feb 16;16(1):105. doi: 10.1186/s12885-016-2138-z
   PubMedGoogle Scholar
• Moores S, Chiu M, Bushey B, et al. A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors. Cancer Res. [2016 Jul 1];76(13):3942–3953. doi: 10.1158/0008-5472.CAN-15-2833
   PubMed Web of Science ®Google Scholar
• Neijssen J, Cardoso R, Chevalier K. Discovery of amivantamab (JNJ-61186372), a buspecific antibody targeting EGFR and MET. J Biol Chem. 2021 Jan;296:100641. doi: 10.1016/j.jbc.2021.100641
   PubMed Web of Science ®Google Scholar
• Wang J, Anderson M, Oleksijew A, et al. ABBV-399, a c-Met antibody-drug conjugate that targets both MET-Amplified and c-Met-overexpressing tumors, irrespective of MET pathway dependence. Clin Cancer Res. [2017 Feb 15];23(4):992–1000. doi: 10.1158/1078-0432.CCR-16-1568
   PubMed Web of Science ®Google Scholar
• Richards D. Exploring alternative antibody scaffolds: Antibody fragments and antibody mimics for targeted drug delivery. Drug Discovery Today. 2018;30:35–46. doi: 10.1016/j.ddtec.2018.10.005
   Google Scholar
• Deonarain M, Yahioglu G, Stamati I, et al. Small-format drug conjugates: a viable alternative to ADCs for solid tumours? Antibodies. 2018 Mar 31;7(2):16. doi: 10.3390/antib7020016
   Web of Science ®Google Scholar
• Deonarain M, Yahioglu G, Stamati I, et al. Emerging formats for next-generation antibody drug conjugates. Expert Opin Drug Discov. 2015 Mar 23;10(5):463–481. doi: 10.1517/17460441.2015.1025049
   PubMed Web of Science ®Google Scholar
• Chen X, Ding G, Gao Q, et al. A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma. PLoS One. [2013 May 13];8(5):e63093. doi: 10.1371/journal.pone.0063093
   PubMed Web of Science ®Google Scholar
• Lu R, Chang Y-L, Chen M-S, et al. Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials. 2011 Apr;32(12):3265–3274. doi: 10.1016/j.biomaterials.2010.12.061
   PubMed Web of Science ®Google Scholar
• Nguyen TD, Bordeau BM, Balthasar JP. Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers. 2023 Jan 24;15(3):713. doi: 10.3390/cancers15030713
   PubMed Web of Science ®Google Scholar
• Miao Z, Hong Y, Zhu T Drug-conjugates, conjugation methods, and uses thereof. United States Patent US 9,801,951 B2. 2017 Oct 31.
   Google Scholar
• Miao Z, Hong Y, Zhu T Drug-conjugates, conjugation methods, and uses thereof. United States Patent US 9,981,046 B2. 2018 May 29.
   Google Scholar
• Miao Z, Chen G, Zhu T, et al. Antibody drug conjugates. United States Patent US 10,590,165 B2. 2020 Mar 17.
   Google Scholar
• Borrebaeck C. Antibody engineering: a practical guide (British medical bulletin). Vol. 4, 2nd. Publisher: Oxford University Press; 1995 Mar 9. p. 117–132. ISBN-10: 0195091507
   Google Scholar
• Yokota T, Milenic D, Whitlow M, et al. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 1992 Jun 15;52(12):3402–3408. PMID: 1596900
   PubMed Web of Science ®Google Scholar
• Dennis M, Jin H, Dugger D, et al. Imaging Tumors with an Albumin-Binding Fab, a Novel Tumor-Targeting Agent. Cancer Res. 2007 Jan 1;67(1):254–261. doi: 10.1158/0008-5472.can-06-2531
   PubMed Web of Science ®Google Scholar
• Fujimori M, Covell D, Fletcher J, et al. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab’)2, and Fab in tumors. Cancer Res. 1989 Oct 15;49(20):5656–5663. PMID: 2790783
   PubMed Web of Science ®Google Scholar
• Vasalou C, Helmlinger G, Gomes B. A Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design. PLoS One. [2015 Mar 18];10(3):e0118977. doi: 10.1371/journal.pone.0118977
   PubMed Web of Science ®Google Scholar
• Milenic D, Yokota T, Filpula D, et al. Construction, binding properties, metabolism, and tumor targeting of a single-chain fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res. 1991 Dec 1;5(23 Part 1):6363–6371. PMID: 1933899
   Google Scholar
• Gao G, Wang Y, Hua H, et al. Marine Antitumor Peptide Dolastatin 10; Biological Activity, Structural Modification and Synthetic Chemistry. Mar Drugs. 2021 Jul;19(7):363. PMID: 34202685. doi: 10.3390/md19070363
   PubMed Web of Science ®Google Scholar
• Zhang J, Liu R, Gao S, et al. Phase I study of A166, an antibody-drug conjugate in advanced HER2-expressing solid tumours. NPJ Breast Cancer. [2023 Apr 18];9(1):28. doi: 10.1038/s41523-023-00522-5
   PubMed Web of Science ®Google Scholar
• Rigby M, Bennett G, Chen L, et al. BT8009; a nectin-4 targeting bicycle toxin conjugate for treatment of solid tumors. Mol Cancer Ther. 2022 Sep 16;21(12):1747–1756. doi: 10.1158/1535-7163.MCT-21-0875
   PubMed Web of Science ®Google Scholar
• Smethurst D, Keen N, Lee K BT8009 clinical trial update. American Association for Cancer Research (AACR) Annual Meeting 2022; 2022 Apr 8-13; New Orleans, Louisiana.
   Google Scholar
• Kang CH, Kim Y, Lee DY, et al. c-Met-Specific Chimeric Antigen Receptor T Cells Demonstrate Anti-Tumor Effect in c-Met Positive Gastric Cancer. Cancers. 2021 Nov 16;13(22):5738. doi: 10.3390/cancers13225738
   PubMed Web of Science ®Google Scholar